For over 50 years, Guthrie has been conducting oncology clinical trials and we are proud to have been affiliated with multiple institutions, including University of Rochester, Cornell University and Vanderbilt. Our current collaborator for National Cancer Institute (NCI) trials is the Mayo Clinic in Rochester, Minnesota. This collaboration allows access to trials through the NCI’s National Clinical Trials Network (NCTN), a research network that provides treatment, screening, and diagnostic trials to over 3,000 clinical sites across the nation. Through this partnership, we’re able to begin clinical trials quickly, reach conclusions faster and offer studies that incorporate precision medicine and novel therapies that otherwise may not be available.  

Leading-edge research delivered locally - As a Guthrie patient you may have the unique opportunity to take part in one or more of nearly 100 clinical research trials that involve new investigational treatments for many cancer types, and the potential to participate in select trials of novel cancer drugs. If you’re at risk for certain types of cancer, screening and prevention trials are also available. Guthrie research scientists are investigating several projects designed to explore cancer trends in our region and how they may affect the next generation of residents.

Clinical Trials

Clinical trials study new ways to prevent, detect and treat cancer. The NCI approves, oversees and provides funding for a large percentage of oncology clinical trials conducted each year in the United States. Guthrie’s participation in this network provides you access to valuable clinical trials without the burden and expense of traveling to a major metropolitan area.

As a result, you receive excellent care locally from the Guthrie Cancer Center team, while still being able to access cutting edge investigational therapies that are offered in large university settings and metropolitan areas. Clinical cancer trials might involve preventive measures and/or treatments, including chemotherapy, biotherapy, supportive care medications, radiation, experimental surgical techniques or devices, lab draws and/or alternative medicines. 

Your physician can present you with options and help you determine whether a clinical trial is right for you. Most clinical trials offered at Guthrie are phase 2 or phase 3 studies which measure safety and efficacy (whether the investigational treatment benefits a specific group of patients).

We work with multiple labs, pharmaceutical groups, biotech companies, and the NCTN to offer you the chance to get innovative treatments, novel therapies and to assist with the future of cancer care. 

Title: LungMap (Screening Protocol for Lung-Map):
Department: Oncology
Diagnosis: Lung- Non-Small Cell
Principal Investigator:

Lowry MD, Philip

Sponsors: SWOG Cancer Research Network
Details (Identifier #): NCT03851445
Title: M21-341 Avanti, A Phase 2/3 multicenter, double blinded, randomized, dose-conversion, active control study examining the efficacy and safety of Armour Thyroid compared to synthetic T4 for the treatment of adults with primary hypothyroidism
Department: Endocrinology
Diagnosis: Endocrine - Growth Hormone
Principal Investigator:

Yavuz MD, Sahzene

Sponsors: AbbVie
Details (Identifier #): NCT06345339
Title: Molecular Analysis for Combination Therapy Choice
(ComboMATCH)
Department: Oncology
Diagnosis: Gastrointestinal - Colon-Rectal
Principal Investigator:

Poulose MD, Joyson

Sponsors: National Cancer Institute
Title: NRG-BR007: A Phase III Clinical Trial Evaluating De-Escalation of Breast Radiation for Conservative Treatment of Stage I, Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer
Department: Oncology
Diagnosis: Breast- Adjuvant
Principal Investigator:

Poulose MD, Joyson

Sponsors: NRG Oncology
Details (Identifier #): NCT04852887
Title: NRG-BR009: A Phase III Adjuvant Trial Evaluating the Addition of Adjuvant
Chemotherapy to Ovarian Function Suppression plus Endocrine Therapy
in Premenopausal Patients with pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score ? 25 (OFSET)
Department: Oncology
Diagnosis: Breast
Principal Investigator:

Wang, Le

Sponsors: National Cancer Institute
Details (Identifier #): NCT05879926
Title: NRG-LU007: Randomized Phase II/III Trial of Consolidation Radiation + Immunotherapy for ES-SCLC: RAPTOR Trial
Department: Oncology
Diagnosis: Lung- Small Cell
Principal Investigator:

Poulose MD, Joyson

Sponsors: NRG Oncology
Details (Identifier #): NCT04402788
Title: OptimICE-PCR: De-Escalation of Therapy in Early-Stage TNBC Patients Who Achieve pCR After Neoadjuvant Chemotherapy With Checkpoint Inhibitor Therapy
Department: Oncology
Diagnosis: Breast
Principal Investigator:

Poulose MD, Joyson

Sponsors: ALLIANCE
Details (Identifier #): NCT05812807
Title: Protocol A081801 Integration of immunotherapy into adjuvant therapy for resected NSCLC: ALCHEMIST chemo-IO (ACCIO) (NCT 04267848)
Department: Oncology
Diagnosis: Lung- Non-Small Cell
Principal Investigator:

Poulose MD, Joyson

Sponsors: National Cancer Institute
Details (Identifier #): NCT04267848
Title: S-11: A multicentre, prospective clinical study analysing outcomes of shoulder arthroplasty with SMR TT Hybrid Glenoid with or without SMR Cementless Finned Short Stem
Department: Orthopedic Surgery
Diagnosis: Orthopedics
Principal Investigator:

Choi M.D., Joseph

Sponsors: LimaCorporate
Details (Identifier #): NCT05314387
Title: S1501, Carvedilol in Preventing Cardiac Toxicity in Patients With Metastatic HER-2-Positive Breast Cancer
Department: Oncology
Diagnosis: Breast- Metastatic
Principal Investigator:

Lowry MD, Philip

Sponsors: SWOG Cancer Research Network
Details (Identifier #): NCT03418961